
    
      The study design of Part 1 was a double-blind, placebo-controlled, randomized, single-dose,
      two-way crossover, followed by two sequential ascending dose periods in 12 healthy
      participants.

      Part 2 was designed to be a double-blind, placebo-controlled, randomized multiple ascending
      dose (MAD) study in 36 healthy participants (12 per study cohort).

      Part 2 was to progress following completion of Part 1, but was not conducted.
    
  